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Response to letter by Chodirker and Chudley
To the Editor:
WehavereadthelettertotheeditorbyDrs.Chodirker&Chud-
ley entitled “Routine Genetic Testing for Asperger Syndrome”
withgreatinterest.Wethankthemfortheirthoughtfulcomments
and recommendations given toward a complex issue. We also
appreciate the opportunity to respond to their letter.
Our initial response is, in general, agreement with the basic
premiseputforth.Thatis,thereisapaucityofpublishedstud-
ies that have specifically looked at a diagnostic yield when As-
perger syndrome is selected out from the rest of the Autism
Spectrum Disorders.
Given the absence of such reports, Drs. Chodirker and
Chudleyreviewedtheliteratureinsearchofdocumentationof
genetic testing abnormalities and persons with Asperger syn-
drome.Whattheyfoundwasahandfulofcasesofpatientswith
Asperger syndrome and abnormal genetic tests. Given the
small number of cases that could be extracted from the litera-
ture, it is not possible to approach a statistical estimate with cer-
tainty.Itisinterestingtonotefromtheirtablethattheyultimately
found 147 patients with Asperger syndrome in the existing re-
ports,with13(9%)positivetests.Itisnotablethatthisisstillinthe
reported range of positive studies from individual reports.
Onepointthatwewouldraiseasdifferentfromtheirinterpre-
tationisinthedismissalofseveralpositivetestsas“unlikely”tobe
etiologicallycausativeor“comorbid.”Wesuggestthattheidenti-
ficationofthesixchromosomeanomaliesshouldbeconsideredas
possibly/probably related. In particular, the association of 22q11
deletions and autisms is well-enough documented that in our
opinion, it should not be dismissed.
Another point of note is that all existing studies share some
sortofselectionbias,bynatureoftheclinicalsourceofpatients
ascertained. Such bias has often been cited as leading to an
overestimate of the diagnostic yield. Still, recent studies that
have not found Fragile X in their patients have suggested that
preselection (either intentional or not) may remove patients
with Fragile X and lead to an underestimate.1,2
Finally, the foundation for what are made as recommenda-
tions based on an existing (albeit incomplete) body of litera-
ture comes down to the proverbial “lumper” versus “splitter”
bias of the genetics provider making the recommendations. In
the latter’s mind, one should not make a recommendation for
genetic testing in Asperger syndrome until there are specific
studies that have addressed that particular issue. Alternatively,
a synthesis of the literature coupled with an understanding of
what a spectrum means could lead one to recommend studies
forallthosewhofallintothespectrumuntilthereisevidenceto
the contrary. With the goal of providing a unifying diagnosis
for as many patients as possible, we fall into this category.
G. Bradley Schaefer, MD
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Little Rock, Arkansas
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Clinical significance of tri-nucleotide repeats in
Fragile X testing: A clarification of American College
of Medical Genetics guidelines
To the Editor:
The purpose of this letter is to reconcile a discrepancy be-
tweentwodocumentsissuedbytheAmericanCollegeofMed-
icalGenetics:theTechnicalStandardsandGuidelinesforFrag-
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Genetics Practice Guidelines statement on diagnostic and car-
rier testing for Fragile X syndrome published in 2005.3 In the
Practice Guidelines, a broad range of 41–60 trinucleotide re-
peats was described for the intermediate or “gray zone” in
Fragile X syndrome based on a research context. That is, re-
search groups used this broader range to identify high-risk
alleles. More relevant to the clinical setting, a range of 45–54
trinucleotiderepeatswasquotedforthegrayzoneintheTech-
nical Standards and Guidelines publication. For a summary of
these ranges please see Table 1.
Differences in the intermediate range then led to discrepan-
cies in the reported ranges for Fragile X premutations. In the
Practice Guidelines, the premutation range is characterized as
61–200 repeats, whereas in the Technical Standards and
Guidelines, the premutation range is defined as 55–200 re-
peats. The American College of Obstetricians and Gynecolo-
gists based their committee opinion on the ACMG Practice
Guidelines, leading to confusion among physicians in inter-
pretation of Fragile X test reports. The ranges for intermediate
and premutation Fragile X alleles quoted in the 2005 Practice
Guidelines have never been used in laboratory practice. After
anextensivereviewoftheliteraturein2005,theQualityAssur-
ance Committee of the ACMG determined that no changes
were required to the ranges originally published in 2001.
Inarecentarticlesummarizingtwomultidisciplinarywork-
shopsfocusedonreproductivecounselingforFMR1premuta-
tioncarriers,Wittenbergeretal.5definedthefourallelicforms
of FMR1 with respect to CGG repeat size. They stated that
consensus has been reached, both in the literature and in the
workshops regarding the size of the premutation at 55–200
repeats,andthefullmutationat200repeatsandtheseranges
agree with those in the Technical Standards and Guidelines as
summarized in Table 1. Wittenberger et al. also stated that con-
sensushasnotyetbeenreachedforthelowerlimitoftheinterme-
diate or gray zone (i.e., 45–54 repeats or 40–54 repeats).
The clinical significance of intermediate and low premuta-
tionsizeallelesis3-fold.First,itistheextenttowhichtheymay
bepronetoinstability,particularlyexpansion,infuturegener-
ations. At the present time, the smallest repeat known to ex-
pand to a full mutation in one generation is 59 CGGs.6,7 Rec-
ognizing this and the fact that there is variation between
laboratoriesandbetweenlaboratorymethodswhendetermin-
ing the exact CGG repeat number, the Laboratory Technical
Standards and Guidelines place the boundaries of the premu-
tation range at 55 and 200 CGG repeats. Quality Assurance
challenges through the College of American Pathologists have
shown that repeat lengths sized using polymerase chain reac-
tion–basedtechniquescanvaryby3–4repeats.TheTechni-
cal Standards and Guidelines allowed for this variation in
choosing55repeatsasthelowerlimitofthepremutationrange
to avoid missing any women at risk for having a child with the
Fragile X syndrome.
Second, the clinical significance is the extent to which these
repeat size alleles increase the risk for premutation-associated
Fragile X tremor ataxia syndrome (FXTAS). FXTAS is a late-
onset neurodegenerative disorder with predominant features
of cerebellar ataxia and intention tremor. Onset is usually in
persons older than 50 years. The risk and/or severity of the
disorder is associated with repeat size, the highest risk being
associated with larger repeats. Among individuals with late-
onset cerebellar ataxia, the prevalence of premutation alleles
was 13 times greater than expected based on its prevalence in
the general population as assessed by a recent meta-analysis.8
Lastly, the clinical significance of intermediate/low premu-
tation repeat size alleles is the extent to which they impose a
risk for premutation-associated ovarian insufficiency. The
prevalence of premature ovarian failure (POF) or cessation of
menses before 40 years of age is about 20%, although it is
highly associated with repeat size: the risk seems to increase
with increasing premutation repeat size between 59 and 99,
thereafter the risk of POF plateaus or even decreases for
women with repeat sizes over 100.9 Premutation carriers have
been identified in about 3% of women with sporadic POF and
in about 12% of women with familial POF.10
Thus, at this point, the risk and/or severity of all three dis-
ordersassociatedwithpremutationalleles(i.e.,instabilitydur-
ing transmission, FXTAS and POF) is established for alleles
55–200 repeats. The risk among the alleles in the lower part of
this range, 55–70 is significantly lower than that in the upper
range, 70–200, for all three disorders.
Table 2 shows the distribution of repeats among the allelic
forms of FMR1 between 41 repeats and 200 repeats as defined
in the two conflicting ACMG publications. The table demon-
stratesthat,weregeneticcounselingtobebasedonthePractice
Table 1
Comparison of the CGG repeat length ranges for each allelic class as defined
by the four reports
Interpretation
Technical
standards2
Practice
guidelines3
ACOG
committee
opinion4
Wittenberger
et al. 5
Unaffected 45 41 41 45
Intermediate,
gray zone
45–54 41–60 41–60 45–54
Premutation 55–200 61–200 61–200 55–200
Full mutation 200 200 200 200
Table 2
Comparison of the clinical interpretation of each allelic class by the two sets
of guidelines
No. repeats
Interpretation according to
technical standards and
guidelines
Interpretation according to
practice guidelines
41–44 Unaffected Intermediate, grayzone
45–54 Intermediate, grayzone Intermediate, grayzone
55–60 Premutation Intermediate, grayzone
61–200 Premutation Premutation
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to have an affected child in the next generation, would not be
counseled appropriately. Furthermore, a greater number of
patients would be identified to have intermediate or gray zone
alleles. As stated above, carrying the label of intermediate or
grayzonecurrentlyhasnoestablishedclinicalsignificanceand
may cause unwarranted concern to families.
In conclusion, the Quality Assurance Committee and the
ProfessionalPracticeandGuidelinesCommitteeoftheACMG
have determined that no changes are required to the ranges
publishedoriginallyin20011andrestatedin2005intheTech-
nical Standards and Guidelines for Fragile X testing.2 The
ACMG Quality Assurance Committee and the Professional
Practice and Guidelines Committee recommend that the fol-
lowing ranges for CGG repeat size be used in the laboratory as
well as in clinical practice:
Unaffected: 45
Intermediate: 45–54
Premutation: 55–200
Full mutation: 200
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